GSK3β Interactions with Amyloid Genes: An Autopsy Verification and Extension.

作者: Timothy J. Hohman , Lori Chibnik , William S. Bush , Angela L. Jefferson , Phillip L. De Jaeger

DOI: 10.1007/S12640-015-9541-0

关键词:

摘要: Glyocogen synthase kinase 3 (GSK3) plays an important role in the pathophysiology of Alzheimer’s disease (AD) through phosphorylation tau. Recent work has suggested that GSK3β also a amyloid pathway AD genetic interactions with APP and APBB2 on vivo measures amyloid. This project extends previously identified genotype to autopsy measure amyloid, while testing same leveraging gene expression data quantified prefrontal cortex. 797 participants (251 cognitively normal, 196 mild cognitive impairment, 350 disease) were drawn from Religious Orders Study Rush Memory Aging Project. A mean score load was calculated across eight brain regions, levels frozen sections dorsolateral cortex using RNA amplification, signals generated Beadstudio. Three SNPs genotyped Illumina 1M genotyping chip. Covariates included age, sex, education, diagnosis. We able evaluate 2 interactions, which interaction between (rs334543) (rs2585590) found this sample (p = 0.04). observed comparable when comparing highest tertile lowest tertile, t(1) −2.03, p 0.043. These results provide additional evidence further suggest is involved both primary neuropathologies disease.

参考文章(24)
Teodoro del Ser, Klaus C. Steinwachs, Hermann J. Gertz, María V. Andrés, Belén Gómez-Carrillo, Miguel Medina, Joan A. Vericat, Pilar Redondo, David Fleet, Teresa León, Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. Journal of Alzheimer's Disease. ,vol. 33, pp. 205- 215 ,(2012) , 10.3233/JAD-2012-120805
Felix Hernandez, Jose J. Lucas, Jesus Avila, GSK3 and tau: two convergence points in Alzheimer's disease. Journal of Alzheimer's Disease. ,vol. 33, pp. 141- 144 ,(2012) , 10.3233/JAD-2012-129025
Christopher J. Phiel, Christina A. Wilson, Virginia M.-Y. Lee, Peter S. Klein, GSK-3α regulates production of Alzheimer's disease amyloid-β peptides Nature. ,vol. 423, pp. 435- 439 ,(2003) , 10.1038/NATURE01640
Claudie Hooper, Richard Killick, Simon Lovestone, The GSK3 hypothesis of Alzheimer's disease. Journal of Neurochemistry. ,vol. 104, pp. 1433- 1439 ,(2008) , 10.1111/J.1471-4159.2007.05194.X
Joshua M. Shulman, Kewei Chen, Brendan T. Keenan, Lori B. Chibnik, Adam Fleisher, Pradeep Thiyyagura, Auttawut Roontiva, Cristin McCabe, Nikolaos A. Patsopoulos, Jason J. Corneveaux, Lei Yu, Matthew J. Huentelman, Denis A. Evans, Julie A. Schneider, Eric M. Reiman, Philip L. De Jager, David A. Bennett, Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology JAMA Neurology. ,vol. 70, pp. 1150- 1157 ,(2013) , 10.1001/JAMANEUROL.2013.2815
Declan M. McLoughlin, Christopher C.J. Miller, The FE65 proteins and Alzheimer's disease. Journal of Neuroscience Research. ,vol. 86, pp. 744- 754 ,(2008) , 10.1002/JNR.21532
Ludovic Martin, Xenia Latypova, Cornelia M. Wilson, Amandine Magnaudeix, Marie-Laure Perrin, Catherine Yardin, Faraj Terro, Tau protein kinases: Involvement in Alzheimer's disease Ageing Research Reviews. ,vol. 12, pp. 289- 309 ,(2013) , 10.1016/J.ARR.2012.06.003
Camila Teixeira Mendes, Fábio Borges Mury, Eloísa de Sá Moreira, Fernando Lopes Alberto, Orestes Vicente Forlenza, Emmanuel Dias-Neto, Wagner Farid Gattaz, Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. European Archives of Psychiatry and Clinical Neuroscience. ,vol. 259, pp. 16- 22 ,(2009) , 10.1007/S00406-008-0828-5
David A. Bennett, Julie A. Schneider, Neelum T. Aggarwal, Zoe Arvanitakis, Raj C. Shah, Jeremiah F. Kelly, Jacob H. Fox, Elizabeth J. Cochran, Danielle Arends, Anna D. Treinkman, Robert S. Wilson, Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. ,vol. 27, pp. 169- 176 ,(2006) , 10.1159/000096129